Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alimu Dayimu

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Lancet (London, England)|February 28, 2026
Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry dataVeronica Pentland, Zoe Thompson, Alimu Dayimu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2025
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate CancerHarveer Dev, Mark Linch, Krishna Narahari, et al.
Nature Cancer|January 6, 2026
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trialRebecca A Burrell, Sanjeev Kumar, Elena Provenzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Lancet (London, England)|February 28, 2026
Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry dataVeronica Pentland, Zoe Thompson, Alimu Dayimu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2025
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate CancerHarveer Dev, Mark Linch, Krishna Narahari, et al.
Nature Cancer|January 6, 2026
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trialRebecca A Burrell, Sanjeev Kumar, Elena Provenzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 3